AstraZeneca: EMA presents findings on vaccine

(CercleFinance.com) - The Pharmacovigilance and Safety Committee (PRAC) of the European Medicines Agency (EMA) today concluded that unusual blood clots with a decrease in the number of blood platelets should be listed as a very rare side effect of Vaxzevria, AstraZeneca's Covid vaccine.


The European Medicines Agency maintains that the benefit/risk ratio of the Anglo-Swedish company's vaccine "remains positive".

In reaching its conclusion, the committee took into account all currently available evidence and consulted a special group of experts.

These "very rare cases" are likely to occur within two weeks of vaccination, the EMA warned, adding that specific risk factors had not been confirmed.

The PRAC noted that blood clots have occurred in veins in the brain (cerebral venous sinus thrombosis, CVST) and abdomen (splanchnic venous thrombosis) and in arteries. Most of the reported cases have occurred in women under 60 years of age.

As with all vaccines, the EMA will continue to monitor the safety and efficacy of the vaccine and provide the public with the latest information, it said in a statement.

While this comes as a sigh of relief, the AstraZenica share is still down 0.7% at the time of writing, underperfoming the FTSE 100, which is up about 1%.



Copyright (c) 2021 CercleFinance.com. All rights reserved.